Hepatocellular Carcinoma: Targeted Therapy provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options.
Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978.
Cushing's syndrome is a relatively rare clinical disorder that is associated with many co-morbidities such as systemic hypertension, diabetes, osteoporosis, impaired immune function and growth impairment in children, all of which severely reduce quality of life and life expectancy.
Metal Carcinogenesis Testing explains fundamental principles of metal carcinogenesis as they are currently understood, and provides detailed practical descriptions of rapid and inexpensive in vitro assay methodology presently in use for the detection of potentially carci- nogenic metals and their compounds.
Chemokines are a superfamily of low molecular weight cytokines that were initially described based on their ability to induce the directed migration of leukocytes to sites of inflammation or injury.
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.
Award winning authors present a comprehensive review of new perspectives in prostate cancer research and open up new directions in the clinical management of prostate cancer.
Clinical Management of Renal Tumors provides an in-depth review of the data relating to the management of renal tumors as well as an updated description regarding pathologic and molecular classification of renal tumors.
Rather than an exhaustive review of all the pathologic conditions of the female breast, Breast Cancer and its Precursor Lesions focuses on the current knowledge, understanding and issues related to breast cancer and its benign lesions that are associated with an increased risk for the subsequent development of cancer.
Bioinformatics can be loosely defined as the collection, classification, storage, and analysis of biochemical and biological information using computers and mathematical algorithms.
Collecting an extensive amount of information from thousands of publications by leading investigators in this rapidly developing field, The Genetics and Molecular Biology of Neural Tumors provides a convenient and up-to-date one volume source for research in neural tumors of various cellular origins.
Cancer chemotherapy can be traced back to the 1940's and since then the world has witnessed the discovery and the important application of several new drugs.
Drawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules.
Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression.
In Bladder Cancer: Moving the Field Forward, Cheryl Lee, David Wood, and a panel of leading authorities and researchers provide a comprehensive review of the related literature, while providing insights into the obstacles of improved survival and discuss methods to advance the field of Bladder Cancer care.
The epidermal gro wth factor (EGF ) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGF receptor therapies.
In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application.
In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma.
Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML).
Transforming Growth Factor-B in Cancer Therapy, Volume II: Cancer Treatment and Therapy The chapters in this volume confer an abundance of knowledge about the current state ofour understanding oftransforming growth factor-B (TGF-B) in cancer treatment and therapy.
Transforming Growth Factor-jl in Cancer Therapy, Volume I: Basicand Clinical Biology The present volume brings together a wealth of information that is fundamental to understanding the roleofTGF-~ in the pathogenesis, prevention, and treatment of cancer.
Extensive research has uncovered a set of molecular surveillance mechanisms - commonly called "e;checkpoints"e; - which tightly monitor cell-cycle processes.
Regional cancer therapies remain important options in the management of malignant disease, in spite of the venue of more targeted agents for systemic therapies.
Prostate Cancer: Biology, Genetics, and the New Therapeutics, Second Edition, reviews new, valuable approaches to the treatment of prostate cancer in men.
The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer.
Apoptosis, Senescence and Cancer provides insight into established practices and research into apoptosis and senescence by thoroughly examining novel and emerging techniques and research in the fields of cell death pathways, senescence growth arrest, drugs and resistance, DNA damage response, and other topics which still hold mysteries for researchers.
